催乳素升高型抗精神病药长期使用与精神分裂症女性乳腺癌风险:芬兰全国嵌套病例对照研究
BACKGROUND: Breast cancer is more common in female patients with schizophrenia than in the general population. It is not known whether treatment with prolactin-increasing antipsychotics contributes to increased odds of breast cancer.…
要点
- 长期(≥5年)使用催乳素升高型抗精神病药与乳腺癌风险升高相关。
- 催乳素保留型药物(氯氮平、喹硫平、阿立哌唑)长期使用未见乳腺癌风险增加。
- 接受催乳素升高型药物治疗的女性应监测催乳素水平并处理高催乳素血症。
核心结论
- 长期暴露于催乳素升高型抗精神病药(而非催乳素保留型)与精神分裂症女性乳腺癌风险升高显著相关。
研究设计与样本
- 1069例乳腺癌病例与5339名对照按年龄和病程1:5匹配,采用条件logistic回归调整共病和合并用药。
临床怎么用
- 对使用催乳素升高型抗精神病药的女性精神分裂症患者,应监测催乳素水平并积极处理高催乳素血症。
- 处方抗精神病药时可考虑催乳素保留型药物(如氯氮平、喹硫平、阿立哌唑)以降低长期乳腺癌风险。
局限性
- ethnicity数据不可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer is more common in female patients with schizophrenia than in the general population. It is not known whether treatment with prolactin-increasing antipsychotics contributes to increased odds of breast cancer. METHODS: We used Finnish nationwide registers of hospital treatment, prescription drug purchases, and cancer diagnoses to do a nested case-control study. Of women with schizophrenia, those with breast cancer (cases) were matched by age and duration of illness with five women without cancer (controls). Cases and controls were aged 18-85 years and exclusion criteria were any previous cancer diagnoses, receipt of organ transplant, mastectomy, or diagnosis of HIV. The main analysis was the association between cumulative exposure to prolactin-increasing drugs and breast cancer. The analyses were done with conditional logistic regression, by adjusting for comorbid conditions and concomitant medications. Ethnicity data were not available. FINDINGS: Of 30 785 women diagnosed with schizophrenia between 1972 and 2014, 1069 were diagnosed with breast cancer between Jan 1, 2000, and Dec 31, 2017. Compared with 5339 matched controls, 1-4 years cumulative exposure (adjusted odds ratio [OR] 0·95, 95% CI 0·73-1·25) or 5 or more years exposure (adjusted OR 1·19, 0·90-1·58) to prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole) was not associated with an increased risk of breast cancer in comparison with minimal exposure (<1 year). When compared with less than 1 year of exposure to prolactin-increasing antipsychotics (all other antipsychotics), 1-4 years of exposure was not associated with an increased risk, but exposure for 5 or more years was associated with an increased risk (adjusted OR 1·56 [1·27-1·92], p<0·001). The risk for developing lobular adenocarcinoma associated with long-term use of prolactin-increasing antipsychotics (adjusted OR 2·36 [95% CI 1·46-3·82]) was higher than that of developing ductal adenocarcinoma (adjusted OR 1·42 [95% CI 1·12-1·80]). INTERPRETATION: Long-term exposure to prolactin-increasing, but not to prolactin-sparing, antipsychotics is significantly associated with increased odds of breast cancer. Monitoring prolactinemia and addressing hyperprolactinemia is paramount in women with schizophrenia being treated with prolactin-increasing antipsychotics. FUNDING: Finnish Ministry of Social Affairs and Health.
引用
- Taipale H, Solmi M, Lähteenvuo M, et al. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021. PMID: 34474013. doi:10.1016/S2215-0366(21)00241-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。